Long-term immunogenicity and safety of a conventional influenza vaccine in patients with type 2 diabetes

Yu Bin Seo, Ji Hyeon Baek, Jacob Lee, Joon-Young Song, Jin Soo Lee, Hee-Jin Cheong, Woo Joo Kim

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

No previous studies have assessed the persistence of immune responses in individuals with diabetes. We conducted this study to evaluate the long-term immunogenicity and safety of an influenza vaccine in type 2 diabetic subjects compared with nondiabetic controls. A randomized and controlled study was conducted at two university hospitals during the 2012-2013 influenza season. The study vaccine was a standard-dose trivalent subunit inactivated intramuscular vaccine. Serum hemagglutination-inhibiting (HI) antibodies were measured at the time of vaccination and 1 month and 6 months after vaccination. Local and systemic reactions were recorded for 7 days. A total of 105 diabetic patients and 108 controls were included in the analysis. One month after vaccination, both the diabetic and nondiabetic groups satisfied all of the criteria of the Committee for Medical Products for Human Use (CHMP), and the immunogenicity profiles were statistically similar between the two groups. Although the vaccine was well tolerated, and all adverse reactions were mild to moderate, there was a tendency toward a reduced incidence of local reactions in the diabetic group. All values in the long-term immunogenicity profiles were statistically similar between the two groups, except for the seroprotection rate for the A/H1N1 influenza virus strain, which was significantly lower in the elderly diabetic group than that in the elderly nondiabetic group. However, in multivariate analysis, long-term immunogenicity was associated with age and prevaccination titer, regardless of diabetes status.

Original languageEnglish
Pages (from-to)1160-1165
Number of pages6
JournalClinical and Vaccine Immunology
Volume22
Issue number11
DOIs
Publication statusPublished - 2015 Nov 1

Fingerprint

Influenza Vaccines
Medical problems
Type 2 Diabetes Mellitus
Vaccination
Vaccines
Safety
Human Influenza
Inactivated Vaccines
Viruses
H1N1 Subtype Influenza A Virus
Subunit Vaccines
Hemagglutination
Antibodies
Multivariate Analysis
Incidence
Serum

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)

Cite this

Long-term immunogenicity and safety of a conventional influenza vaccine in patients with type 2 diabetes. / Seo, Yu Bin; Baek, Ji Hyeon; Lee, Jacob; Song, Joon-Young; Lee, Jin Soo; Cheong, Hee-Jin; Kim, Woo Joo.

In: Clinical and Vaccine Immunology, Vol. 22, No. 11, 01.11.2015, p. 1160-1165.

Research output: Contribution to journalArticle

@article{2b8631862e8f4843b2fd4985dadb2722,
title = "Long-term immunogenicity and safety of a conventional influenza vaccine in patients with type 2 diabetes",
abstract = "No previous studies have assessed the persistence of immune responses in individuals with diabetes. We conducted this study to evaluate the long-term immunogenicity and safety of an influenza vaccine in type 2 diabetic subjects compared with nondiabetic controls. A randomized and controlled study was conducted at two university hospitals during the 2012-2013 influenza season. The study vaccine was a standard-dose trivalent subunit inactivated intramuscular vaccine. Serum hemagglutination-inhibiting (HI) antibodies were measured at the time of vaccination and 1 month and 6 months after vaccination. Local and systemic reactions were recorded for 7 days. A total of 105 diabetic patients and 108 controls were included in the analysis. One month after vaccination, both the diabetic and nondiabetic groups satisfied all of the criteria of the Committee for Medical Products for Human Use (CHMP), and the immunogenicity profiles were statistically similar between the two groups. Although the vaccine was well tolerated, and all adverse reactions were mild to moderate, there was a tendency toward a reduced incidence of local reactions in the diabetic group. All values in the long-term immunogenicity profiles were statistically similar between the two groups, except for the seroprotection rate for the A/H1N1 influenza virus strain, which was significantly lower in the elderly diabetic group than that in the elderly nondiabetic group. However, in multivariate analysis, long-term immunogenicity was associated with age and prevaccination titer, regardless of diabetes status.",
author = "Seo, {Yu Bin} and Baek, {Ji Hyeon} and Jacob Lee and Joon-Young Song and Lee, {Jin Soo} and Hee-Jin Cheong and Kim, {Woo Joo}",
year = "2015",
month = "11",
day = "1",
doi = "10.1128/CVI.00288-15",
language = "English",
volume = "22",
pages = "1160--1165",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Long-term immunogenicity and safety of a conventional influenza vaccine in patients with type 2 diabetes

AU - Seo, Yu Bin

AU - Baek, Ji Hyeon

AU - Lee, Jacob

AU - Song, Joon-Young

AU - Lee, Jin Soo

AU - Cheong, Hee-Jin

AU - Kim, Woo Joo

PY - 2015/11/1

Y1 - 2015/11/1

N2 - No previous studies have assessed the persistence of immune responses in individuals with diabetes. We conducted this study to evaluate the long-term immunogenicity and safety of an influenza vaccine in type 2 diabetic subjects compared with nondiabetic controls. A randomized and controlled study was conducted at two university hospitals during the 2012-2013 influenza season. The study vaccine was a standard-dose trivalent subunit inactivated intramuscular vaccine. Serum hemagglutination-inhibiting (HI) antibodies were measured at the time of vaccination and 1 month and 6 months after vaccination. Local and systemic reactions were recorded for 7 days. A total of 105 diabetic patients and 108 controls were included in the analysis. One month after vaccination, both the diabetic and nondiabetic groups satisfied all of the criteria of the Committee for Medical Products for Human Use (CHMP), and the immunogenicity profiles were statistically similar between the two groups. Although the vaccine was well tolerated, and all adverse reactions were mild to moderate, there was a tendency toward a reduced incidence of local reactions in the diabetic group. All values in the long-term immunogenicity profiles were statistically similar between the two groups, except for the seroprotection rate for the A/H1N1 influenza virus strain, which was significantly lower in the elderly diabetic group than that in the elderly nondiabetic group. However, in multivariate analysis, long-term immunogenicity was associated with age and prevaccination titer, regardless of diabetes status.

AB - No previous studies have assessed the persistence of immune responses in individuals with diabetes. We conducted this study to evaluate the long-term immunogenicity and safety of an influenza vaccine in type 2 diabetic subjects compared with nondiabetic controls. A randomized and controlled study was conducted at two university hospitals during the 2012-2013 influenza season. The study vaccine was a standard-dose trivalent subunit inactivated intramuscular vaccine. Serum hemagglutination-inhibiting (HI) antibodies were measured at the time of vaccination and 1 month and 6 months after vaccination. Local and systemic reactions were recorded for 7 days. A total of 105 diabetic patients and 108 controls were included in the analysis. One month after vaccination, both the diabetic and nondiabetic groups satisfied all of the criteria of the Committee for Medical Products for Human Use (CHMP), and the immunogenicity profiles were statistically similar between the two groups. Although the vaccine was well tolerated, and all adverse reactions were mild to moderate, there was a tendency toward a reduced incidence of local reactions in the diabetic group. All values in the long-term immunogenicity profiles were statistically similar between the two groups, except for the seroprotection rate for the A/H1N1 influenza virus strain, which was significantly lower in the elderly diabetic group than that in the elderly nondiabetic group. However, in multivariate analysis, long-term immunogenicity was associated with age and prevaccination titer, regardless of diabetes status.

UR - http://www.scopus.com/inward/record.url?scp=84945531231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945531231&partnerID=8YFLogxK

U2 - 10.1128/CVI.00288-15

DO - 10.1128/CVI.00288-15

M3 - Article

C2 - 26376926

AN - SCOPUS:84945531231

VL - 22

SP - 1160

EP - 1165

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 11

ER -